Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Ga-NOTA-MAL-Cys39-exendin-4 PET/CT in Insulinoma
NCT04185350Phase 1Unknown
- Sponsor
- Nanjing First Hospital
- Start
- May 2019
- Primary completion
- Apr 2020
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 68Ga-NOTA-MAL-Cys39-exendin-4 in insulinoma, sponsored by Nanjing First Hospital. Primary endpoint: Standardized uptake value at 1 year. Status: unknown.
02
Drugs
68Ga-NOTA-MAL-Cys39-exendin-4
03
Conditions
insulinoma
Beyond the preview
Go deeper on NCT04185350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04185350.